Chairman of the Board, OraSure Technologies, Inc. / Founder, Pittencrieff Glen Associates
Douglas G. Watson became a member of the Board in May 2002 and became Chairman of the Board in March 2003. Since July 1999, Mr. Watson has been Chief Executive Officer of Pittencrieff Glen Associates, a leadership and management consulting firm, which he founded. Prior to that, Mr. Watson served as President and Chief Executive Officer of Novartis Corporation, the U.S. subsidiary of Novartis A.G., President and Chief Executive Officer of Ciba-Geigy Corporation, President of Ciba’s US Pharmaceuticals Division and Senior Vice President of Planning and Business Development of Ciba’s U.S. Pharmaceuticals Division.
Mr. Watson holds an M.A. degree in pure mathematics from Churchill College, Cambridge University, and is a member of the Chartered Institute of Management Accountants. Mr. Watson also serves on the Boards of BioMimetic Therapeutics, Inc., Delcath Systems, Inc., Dendreon Corporation, and Genta Inc.
Vice President, Finance and Chief Financial Officer for BioRexis Pharmaceutical Corporation
Michael Celano became a member of the Board in October 2006. Mr. Celano has served as Chief Financial Officer of Kensey Nash Corporation, a biomaterials company, since March 2009. He was Managing Director of Aon Risk Services from August 2007 to December 2008. From September 2004 to May 2007, Mr. Celano served as Vice President, Finance and Chief Financial Officer for BioRexis Pharmaceutical Corporation, a biopharmaceutical company. Before joining BioRexis, Mr. Celano served as a partner with KPMG LLP, in charge of its Mid-Atlantic Life Sciences Practice, from June 2002 to August 2004, and was co-leader of its National Life Science Practice. Prior to joining KPMG, Mr. Celano was co-leader of the Life Science Practice for Arthur Andersen.
Mr. Celano is a Certified Public Accountant and holds a B.S. degree in Accounting from St. Joseph’s University.
President and CEO, The University City Science Center
Stephen S. Tang became a member of the Board in April 2011. He is currently the President and CEO of The University City Science Center, an urban research park and business incubator based in Philadelphia, a position he has held since January 2008. Previously, Dr. Tang was with Olympus America Inc. from 2005 to 2008, where he served as the Company’s first Group Vice President for Life Science. Prior to Olympus, from 2000 to 2004, Dr. Tang was President, Chief Executive Officer and a Director of Millennium Cell Inc., a NJ-based energy technology firm. Before his work at Millennium Cell, Dr. Tang served as Vice President and Managing Director of the global pharmaceutical and healthcare practice of A.T. Kearney Inc. from 1996 to 2000.
Dr. Tang received his B.S. in Chemistry from the College of William and Mary and his M.S. and PH.D. in Chemical Engineering from Lehigh University. He also earned a M.B.A. from The Wharton School of Business at the University of Pennsylvania.
Senior Vice President, Federal Government Relations for Assurant Incorporated
Ronny B. Lancaster became a member of the Board in May 2003. Mr. Lancaster has served as Senior Vice President, Federal Government Relations of Assurant, Inc., a provider of specialty insurance and insurance-related products and services since September 2005. From 2003 until September 2005, Mr. Lancaster served in various capacities at the Morehouse School of Medicine in Atlanta, including Chief Operating Officer. Prior to that, Mr. Lancaster was Executive Assistant to the Secretary and Principal Deputy Assistant Secretary for Planning and Evaluation at the U.S. Department of Health and Human Services. Prior to serving at HHS, Mr. Lancaster was General Counsel of Hamilton Enterprises, Inc., Senior Washington Representative for Blue Cross/Blue Shield Association, and Chief of the Division of Fee-For-Service Plans at the U.S. Office of Personnel Management.
Mr. Lancaster received his B.A. in Economics from the Catholic University of America, his M.B.A. from the Wharton School of the University of Pennsylvania, and his J.D. degree from The Georgetown University Law Center. He is also admitted to the Bars of Pennsylvania and the District of Columbia. Mr. Lancaster currently serves on the Board of Immucor, Inc. and on the Medical Advisory Board of Henry Schein, Inc.
President and CEO, OraSure Technologies, Inc.
Douglas A. Michels joined OraSure Technologies, Inc. in June 2004, as President and Chief Executive Officer and as a member of the Board of Directors. He is an Executive Officer and member of the Executive Committee.
Prior to joining the Company, Mr. Michels spent 19 years with Johnson & Johnson and seven years with Abbott Laboratories. At Johnson & Johnson, he was President, International, for Ortho-Clinical Diagnostics, Inc., and President of Johnson & Johnson Health Care Systems, Inc. He also held numerous General Management and Marketing and Sales positions, in both medical devices and diagnostics. While at Abbott Laboratories, he held various sales and marketing positions.
Mr. Michels currently serves as a member of the U.S. Presidential Advisory Council on HIV/AIDS (PACHA) and serves on the Board of St. Luke's Hospital and Health Network in Bethlehem, PA and West Pharmaceutical Services, Inc, in Lionville, PA. Mr. Michels previously served on the Board of the National Blood Foundation, the Board of the National Committee for Quality Health Care, and the Coalition to Protect America's Health Care.
Mr. Michels received a B.S. degree in Public Health Administration from the University of Illinois in 1978 and an MBA from Rutgers University in 1990.
Retired Chairman and Chief Executive Officer, Bausch & Lomb
Gerald M. Ostrov became a member of the Board in November 2011. He most recently served as Chairman and CEO of Bausch & Lomb, an eye health company dedicated to perfecting vision and enhancing life for consumers around the world. He held this position from 2008 to 2010.
Prior to Bausch & Lomb, Mr. Ostrov served as Company Group Chairman, Worldwide Vision Care, for Johnson & Johnson, where he led the company’s global Vision Care businesses from 1998 through 2006. He also held positions for Johnson & Johnson as President of its Personal Products business, and then Company Group Chairman for its North American Consumer and Personal Care businesses. Prior to his work at Johnson & Johnson, Mr. Ostrov served as President of Ciba Consumer Pharmaceuticals for Ciba-Geigy AG from 1985-1991.
Mr. Ostrov holds a B.S. degree in industrial engineering and operations research from Cornell University, and an M.B.A. from Harvard University.
Principal and Founder of Patrick Consulting
Charles W. Patrick became a member of the Board in January 2006. Since 2000, he has served as Principal of Patrick Consulting, a management consulting firm that helps diagnostic and technology companies develop sales, marketing and distribution strategies. Mr. Patrick is also the President and Co-owner of ADS Golf, Inc. During the period September 2000 through April 2001, he served as the President and Chief Executive Officer of Call Nexus, Inc., a provider of virtual call center services. From 1990 to 2000, Mr. Patrick served as Vice President of Sales and Marketing for Biosite Diagnostics, a medical diagnostics company, and had primary responsibility for developing and achieving Biosite’s strategic sales and marketing objectives. Prior to his time at Biosite, Mr. Patrick served as World Wide Group Marketing Manager and held several other sales and marketing positions for the Diagnostics Division of Abbott Laboratories.
Mr. Patrick received a B.A. in Communications/Journalism from the University of Central Florida. Mr. Patrick currently serves on the Board of diaDexus, Inc.
President of The Pringle Company
Roger L. Pringle has served on the Board since September 2000. Mr. Pringle is the Founder and President of The Pringle Company, an executive search and strategy consulting firm. He is presently a corporate director for three companies including OraSure Technologies, Inc., Northwest Bank and Prolifiq Software, Inc., and he serves as a retained advisor to Tillamook Cheese. He previously served as Chairman of the board for Epitope, Inc., a predecessor company to OraSure and on the board of Agritope, Inc., a plant genetics subsidiary of Epitope. He has also served on the boards of West Bank Oregon, Bank of the Northwest, North Pacific Group, Veris Industries, Inc., and The ODS Companies. Prior to founding The Pringle Company Mr. Pringle spent six years with Ernst & Young as a Principal in their management consulting organization and five years with Hyster Company. Concurrent with his firm’s activities and his board service, Mr. Pringle is an active angel investor.
Mr. Pringle has a B.S. from Oregon State University and an MBA from the University of Oregon.
Chief Operating Officer and Chief Financial Officer, OraSure Technologies, Inc.
Ronald H. Spair joined the Company in November 2001, as Executive Vice President and Chief Financial Officer and was promoted to Chief Operating Officer and Chief Financial Officer at which time he also became a member of the Board of Directors in October 2006. He is an Executive Officer and member of the Executive Committee.
Mr. Spair has extensive senior financial experience in the pharmaceutical and biotechnology industries. Before joining OraSure he was with Delsys Pharmaceutical Corporation as Vice President and Chief Financial Officer. Prior to Delsys, he was Chief Financial Officer for three public companies – Supergen, Inc., Sparta Pharmaceuticals, Inc., and Envirogen, Inc. During this period, Mr. Spair had responsibility for directing finance, accounting, financial planning, treasury, human resources, risk management and information technology matters at these companies. Mr. Spair has also had extensive experience negotiating mergers and acquisitions, development and licensing transactions and corporate financings.
Mr. Spair is a Certified Public Accountant and received both his B.S. in Accounting and his MBA from Rider College.
|Print Page | E-mail Page | RSS Feeds | E-mail Alerts | IR Contacts | Financial Tear Sheet|